MktsMarkets

Unicycive Therapeutics, Inc.
NASDAQ: UNCYKey statistics
UNCY News
Stories mentioning UNCY from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,607 | 2,236 | 2,964 | 1,750 | 2,171 | 5,288 | 3,045 | 4,868 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 8,437 | 7,223 | 7,342 | 6,963 | 7,989 | 9,261 | 6,251 | 7,401 |
| Operating Income (Loss) | (8,437) | (7,223) | (7,342) | (6,963) | (7,989) | (9,261) | (6,251) | (7,401) |
| Interest Income | 394.00 | 352.00 | 279.00 | 155.00 | 226.00 | 314.00 | 416.00 | 462.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (12,823) | (14,667) | (6,011) | (6,447) | 570.00 | (21,525) | (4,096) | 9,855 |
| Earnings Per Share (Basic) | (0.54) | (0.92) | (0.33) | (0.52) | 0.04 | (3.21) | (0.46) | 0.80 |
| Earnings Per Share (Diluted) | (0.54) | (0.92) | (0.33) | (0.52) | (0.50) | (3.21) | (0.46) | (1.50) |
| Weighted Average Shares Outstanding (Basic) | 23,908 | 15,887 | 18,065 | 12,302 | 11,682 | 6,699 | 8,894 | 3,791 |
| Weighted Average Shares Outstanding (Diluted) | 23,908 | 15,887 | 18,065 | 12,302 | 12,383 | 6,699 | 8,894 | 9,405 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About UNCY
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a stock listed on the Nasdaq Stock Market under the ticker symbol UNCY. It last traded at $3.55 (Nov 13, 2026, 4:00 PM ET), down 2.5% on the day. That gives Unicycive Therapeutics a market capitalisation of $100.6M.
Over the past 52 weeks UNCY has traded between $3.33 and $8.74.
For the quarter ended Mar 31, 2026 it reported a net loss of $12.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$12.8M |
| Dec 31, 2025 | — | -$14.7M |
| Sep 30, 2025 | — | -$6.0M |
| Jun 30, 2025 | — | -$6.4M |
From Unicycive Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…